#Bioretec #Finland #healthcare #Helsinki #RemeOs

Bioretec Ltd Completes Successful Rights Issue

In a major development for the Finnish medical device company Bioretec Ltd, the firm has successfully concluded its rights issue and registered a significant number of new shares with the trade register. This move not only strengthens the company's capital base but also highlights its ongoing commitment to advancing orthopedic care through innovative technologies.

Rights Issue Overview

As announced earlier, Bioretec has completed the rights issue, an offering that led to the subscription of a total of 1,286,801,534 new shares. Additionally, the company issued 24,196,337 new shares to Stephen Industries Inc Oy as part of an underwriting fee, amounting to a total registration of 1,341,785,963 shares. This expansion reflects the market's confidence in Bioretec's growth strategy, particularly as it focuses on biodegradable implant technologies that are transforming orthopedic procedures around the globe.

The newly registered shares will provide investors with equal rights to Bioretec's existing shares, facilitating a smoother integration into the company’s overall offering. Trading in the new shares is anticipated to begin on Nasdaq First North Growth Market Finland shortly after the registration date, aligning with the company's goal to increase its market presence.

Innovations in Orthopedic Care

Bioretec stands at the forefront of orthopedic innovations with its RemeOs™ product line, which utilizes a high-performance magnesium alloy and hybrid composites designed for enhanced surgical outcomes. Unlike traditional implants, RemeOs products are absorbed by the body over time and replaced with bone tissue, mitigating the need for secondary surgeries to remove implants and significantly improving patient recovery experiences.

The company secured its first market authorization for the RemeOs implants in the United States back in March 2023, demonstrating its commitment to expanding its reach across key global markets. Furthermore, the CE mark approval received in January 2025 signifies Bioretec's adherence to European medical standards, which positions the company favorably in a competitive landscape.

Bioretec's Activa product line is another leap forward in the field, featuring fully bioabsorbable orthopedic implants crafted from a proprietary, self-reinforced PLGA. This innovative product line is also CE marked and FDA cleared, catering to a wide range of indications in both adult and pediatric patients.

Strengthening Investor Relations

With this successful capital infusion from the rights issue, Bioretec is poised to further its research and development efforts, which are critical for ongoing innovation in the field of biodegradable orthopedic implants. CEO Sarah van Hellenberg Hubar-Fisher expresses optimism about the company’s future, as the enhanced resources will allow Bioretec to explore new opportunities and refine existing products to ensure they meet the high standards of modern healthcare.

The completed rights issue underscores strong investor trust, enabling Bioretec to continue paving the way in orthopedic treatments that align with patient-centric care principles. This focus on healing through absorption rather than the traditional fixation methods sets Bioretec apart from competitors in the market.

Conclusion

As Bioretec Ltd embarks on this next chapter of growth, the company continually emphasizes its mission to improve patient outcomes through innovative technology. The recent completion of the rights issue marks a significant milestone, heralding exciting advancements for the firm and its loyal investor base. For more information on Bioretec and its innovative solutions, please visit their official website at www.bioretec.com.